Seven Fleet Capital Management LP Acquires New Shares in Evolus, Inc. $EOLS

Posted by Brenda Bartman on Aug 27th, 2026

Seven Fleet Capital Management LP acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 78,057 shares of the company’s stock, valued at approximately $541,716. Seven Fleet Capital Management LP owned about 0.12% of Evolus as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Larson Financial Group LLC increased its stake in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Evolus during the fourth quarter worth approximately $34,000. Legal & General Group Plc acquired a new position in shares of Evolus in the second quarter valued at approximately $40,000. Wexford Capital LP bought a new position in Evolus in the 3rd quarter valued at about $37,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Evolus by 340.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after acquiring an additional 5,691 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Price Performance

EOLS stock remained flat at $8.88 during mid-day trading on Friday. 1,059,311 shares of the company’s stock were exchanged, compared to its average volume of 1,043,286. The business has a 50 day moving average of $7.00 and a 200 day moving average of $5.89. Evolus, Inc. has a twelve month low of $3.86 and a twelve month high of $9.12. The stock has a market cap of $586.52 million, a P/E ratio of -17.08 and a beta of 1.35.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on EOLS shares. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. BTIG Research reaffirmed a “buy” rating and issued a $13.00 target price on shares of Evolus in a research report on Wednesday, June 17th. Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Evolus in a report on Tuesday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.50.

Check Out Our Latest Stock Analysis on Evolus

Evolus Company Profile

(Free Report)

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.